基于黄芪甲苷VII与黄芪多糖纳米载体的季节性流感A(H3N2)疫苗佐剂系统开发
研究在瑞士白化小鼠中评估新型纳米载体系统APNS(含黄芪多糖)及其含黄芪甲苷VII的制剂ANS对季节性流感A(H3N2)灭活疫苗的免疫调节作用。免疫后4周检测抗体、细胞因子及脾细胞增殖,APNS增强IgG1抗体滴度呈Th2型应答,ANS产生IFN-γ、IL-17A和IgG2a呈Th1/Th2平衡及Th17应答。结果表明APNS和ANS可作为季节性流感A疫苗的良好佐剂/载体候选。
要点
- APNS通过升高IgG1抗体滴度介导Th2型免疫应答。
- ANS通过产生IFN-γ、IL-17A和IgG2a诱导Th1/Th2平衡及Th17应答。
- APNS和ANS可作为季节性流感A疫苗的佐剂/载体候选。
核心结论
- APNS和ANS是可用于季节性流感A疫苗的良好佐剂/载体系统候选。
研究设计与样本
- 将灭活H3N2单独或与受试化合物/制剂联合肌肉注射至瑞士白化小鼠,免疫后4周评估抗体、细胞因子应答及脾细胞增殖。
主要发现
- APNS通过升高IgG1抗体滴度表现Th2介导的应答。
- ANS通过产生IFN-γ、IL-17A和IgG2a表现朝向Th1/Th2平衡及Th17的应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adjuvants are chemical/biological substances that are used in vaccines to increase the immunogenicity of antigens. A few adjuvants have been developed for use in human vaccines because of their limitations including lack of efficacy, unacceptable local or systemic toxicity, the difficulty of manufacturing, poor stability, and high cost. For that reasons, novel adjuvants/adjuvant systems are under search. Astragaloside VII (AST-VII), isolated from Astragalus trojanus, exhibited significant cellular and humoral immune responses. The polysaccharides (APS) obtained from the roots of Astragalus species have been used in traditional Chinese medicine and possess strong immunomodulatory properties. In the present study, the immunomodulatory effects of a newly developed nanocarrier system (APNS: APS containing carrier) and its AST-VII containing formulation (ANS: AST-VII + APNS), on seasonal influenza A (H3N2) vaccine were investigated. Inactivated H3N2 alone or its combinations with test compounds/formulations were intramuscularly injected into Swiss albino mice. Four weeks after immunization, the immune responses were evaluated in terms of antibody and cytokine responses as well as splenocyte proliferation. APNS demonstrated Th2 mediated response by increasing IgG1 antibody titers, whereas ANS showed response towards Th1/Th2 balance and Th17 by producing of IFN-γ, IL-17A and IgG2a. Based on these results, we propose that APNS and ANS are good candidates to be utilized in seasonal influenza A vaccines as adjuvants/carrier systems.
引用
- Yakuboğulları N, Genç R, Çöven F, et al. Development of adjuvant nanocarrier systems for seasonal influenza A (H3N2) vaccine based on Astragaloside VII and gum tragacanth (APS). Vaccine. 2019. PMID: 31155418. doi:10.1016/j.vaccine.2019.05.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。